In this interview, Kyle Haraldsen, Chief Technology Officer of Lyndra Therapeutics, explores how the drug delivery landscape is evolving to increase focus on patient centricity and sustainability through development of long-acting, oral-delivery technologies.
How has the drug delivery landscape evolved in recent years?
Over the last few years, we have witnessed increasingly impressive innovations in the drug delivery landscape that have advanced our ability to prevent and treat disease. Everything from the mRNA technology that made the rapid development of COVID vaccines possible to antibody-drug conjugates enabling the binding of monoclonal antibodies to cancer receptors. One thing we haven’t seen a lot of, though, is improvements in the oral pill. Many of the pills we take today are not dissimilar to the aspirin pill from 100 years ago.
Some therapeutic areas, however, have seen an evolution towards developing longer acting medicines. There are generally two ways to do this – through chemistry of the drug molecule itself and through advanced delivery technology. As an industry, we tend to be more focused on the chemistry part, although there are some innovative things happening in delivery modalities thanks to advances in technology, too (eg, liposomal delivery, transdermal delivery, implantable devices).
For either focus, we need to make sure we’re creating things that patients actually want – being truly patient-centric. For example, research consistently shows that patients and caregivers prefer oral pills over medicine delivered via injection. It’s also human nature to be more comfortable with things that are already familiar to us.
Are you looking to explore how lipid formulations in softgels can enhance drug absorption and bioavailability. Register for our upcoming webinar to find out!
3 September 2025 | 3:00 PM BST | FREE Webinar
This webinar will delve into the different types of lipid formulations, such as solutions, suspensions, emulsions, and self-(micro)emulsifying systems. Applications span diverse therapeutic areas including HIV therapy, oncology, immunosuppressants, and emerging treatments like medicinal cannabis (eg, CBD).
What You’ll Learn:
Lipid formulation development and screening tools for optimisation
Key steps in scale-up and industrialisation to ensure consistency and efficiency
Impact of lipid-based softgels on drug delivery and patient outcomes.
This is why we’re focused on developing long-acting oral medicines at Lyndra. It’s a drug delivery method that patients know and like, and the potential benefits of long-acting medicines are clear: they can reduce patient and caregiver burden, increase medication adherence and, in turn, produce better patient outcomes.
Developing a long-acting delivery system at Lyndra
Lyndra has created a capsule that looks the same as the capsules people are used to taking, yet it has a proprietary coating that makes it easy to swallow and maintains its integrity until it reaches the acidic environment of the stomach. Once exposed to the stomach’s aqueous environment, the capsule dissolves and the arms within the capsule begin to elute the drug substance. Consistent elution of drug is made possible by suspending the drug in a polymer matrix. This controls the rate that stomach fluid enters into the drug arm to solubilise and elute the API. This technology enables the drug delivery platform to stay in the stomach for several days.
What are the top three trends in drug delivery?
There are several trends I could speak about, including an increased patient desire for self-administrable and low-cost options for injectable drug delivery systems and innovative uses of existing drug delivery systems/medications to target new therapeutic areas. There’s also a strengthening movement around sustainability as we innovate.
With lots of momentum in the space, here are three top trends I’ve been particularly focused on:
Long acting gets longer acting: We’re creating a new category of medicines at Lyndra called “long-acting oral” therapies, so the growing demand from industry and patients here is a top priority for me. Pharmaceutical companies are taking notice and investing in the next generation of drug delivery technologies that will improve the dosing frequency of their medicines. Currently, we’re seeing this play out in the glucagon-like peptide-1 (GLP-1) space, as companies race against one another to create even longer-acting injectables and/or oral versions to compete for market share. In addition to helping patients, the creation of new long-acting drug delivery technologies can have major positive impacts for the industry. In some cases, creating longer-acting versions of a medicine may be an opportunity for patent extension. It could also bring new life to chemical entities that were previously not deemed viable medicines due to a burdensome dosing frequency.
Oral drug delivery continues to be the ‘holy grail’: Companies manufacturing injectables are feeling pressure to offer oral options of their therapies to patients. For many years, the complexities of biologics manufacturing, the rapid degradation of medicines within the harsh environment of the gastrointestinal tract, and challenges with gastrointestinal permeability made this a challenging feat to accomplish. But recent advances in technology and processes are making it possible to deliver more medicines through oral pills. In some cases, companies that launched their drug to market as an injectable are now reinvesting some of those revenues to develop oral versions. It will be fascinating to see how companies continue to evolve by bringing injectables into oral therapeutic options, and the impact on patient preference and uptake.
Patient centricity: Overall, the industry is focused on better meeting patient needs. This includes providing new routes for care and medication access with the growth of telehealth companies and the creation of medication delivery methods, packaging and support tools that aid their ease of use. We’ve seen this trend amplified in the GLP-1 space, with self-injection options offering patients a more convenient and discreet option for managing their medications. It is important we continue to consider and prioritise the things patients care about, including accessibility, affordability and environmental sustainability.
Please share an update on Lyndra’s remaining pivotal safety trial for the oral weekly risperidone (LYN-005) treatment for schizophrenia, planned for 2024.
In January 2024, we announced positive data from our pivotal Phase III study, comparing the pharmacokinetic profile of oral weekly risperidone (LYN-005) with immediate-release Risperdal administered daily to adults living with schizophrenia and schizoaffective disorder. Later this year, we will be advancing LYN‑005 into its remaining pivotal safety study and anticipate results will be announced in 2025, shortly followed by an NDA submission.
What are the two biggest challenges of manufacturing long-acting oral treatments?
Longer feedback loops: The development of a long-acting pill means testing cycles also take longer. For example, if we’re doing dissolution testing for a pill that releases drug over a month, we really need at least 28 days to get results. Lyndra has created its own in-vitro testing technologies to help accelerate and streamline this process.
Disruptive technology is novel: What Lyndra is doing with its LYNX® drug delivery platform (see box) is completely new. This adds complexity to the manufacturing process since we are also inventing new manufacturing systems, tools and processes. We do this while ensuring regulatory compliance throughout each step.
What two developments in long-acting oral treatments are you most excited about in the next five to 10 years?
As I noted earlier, we haven’t seen much development in long-acting orals over the last several decades, so any potential innovation in this space is incredibly exciting to me. I’m hoping to see more and more companies, and more and more investors, get as excited about the potential of long-acting oral therapies as we are. My sincere hope is that we see an infusion of investment in this space because I truly believe having access to long-acting oral therapies can be game changing for patients and our industry more broadly.
A few specific things that excite me are:
The potential for long-acting oral therapies in polypharmacy. Lyndra’s LYNX platform has the capability to put different drugs in different arms. Pills taken individually can have different absorption profiles – but when combined in the platform, there could be a potential benefit of ensuring that the drugs are delivered optimally throughout the dosing period for a more synergistic effect. This needs more research, but I believe it could be a tremendous opportunity.
I’m also optimistic that the platform will show our industry that we don’t need to give up on oral delivery of complex compounds – we don’t have to settle for injectables or other forms of delivery because a compound wouldn’t make a good daily pill. I believe the platform provides an opportunity to overcome some existing limitations and to open up new possibilities of long-acting oral drug delivery to improve patient lives and outcomes.
Kyle Haraldsen is Chief Technology Officer of Lyndra Therapeutics, where he leads product and platform R&D activities for the LYNX® drug delivery platform and manufacturing strategy. Additionally, he co‑chairs the Science & Technology Committee in partnership with Lyndra’s Chief Medical Officer Dr Richard Scranton. Prior to joining Lyndra, Kyle served as Chief Technical Operations Officer at Saniona, where he established the technical operations department and led efforts to develop a complex long-acting multi-product formulation of their lead asset. Before Saniona, he held roles of increasing responsibility in technical operations and manufacturing at AMAG Pharmaceuticals, ending as Vice President – Technical Operations & Project Management. Kyle holds a bachelor’s degree in chemical engineering from Northeastern University and studied drug delivery as part of a short course at MIT. He is an Advisory Board member for the Friends of Parkinson’s and an Industry Council member for the Dearborn STEM Academy.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.